Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.

Teclegiorgis GebremariamYiyou GuShakti SinghTherese M KittAshraf S Ibrahim

Published in: The Journal of antimicrobial chemotherapy (2021)

The L-AMB/isavuconazonium sulphate combination demonstrated greater activity versus monotherapy in immunosuppressed mice infected with either of the two most common causes of mucormycosis. These studies warrant further investigation of L-AMB/isavuconazonium sulphate combination therapy as an optimal therapy of human mucormycosis.

Keyphrases

combination therapy
endothelial cells
induced pluripotent stem cells
type diabetes
randomized controlled trial
high fat diet induced
cancer therapy
pluripotent stem cells
clinical trial
mesenchymal stem cells
metabolic syndrome
study protocol
open label
case control
bone marrow
insulin resistance
skeletal muscle